Tirofiban

Trade names

AGGRASTAT

Actions

• Reversible glycoprotein IIb/IIIa inhibitor.

Route of Administration

Intravenous

Bioavailability

100%

Plasma protein binding

Dose dependent, low.

Time to peak plasma concentration

Dose dependent

Plasma steady state

The steady state volume of distribution of Tirofiban ranges from 22 to 42 liters.

Half-life

2 h

Elimination

Renal 39-69%.

Duration of action

2–4 h

Reversible platelet inhibition

Yes

Recommended dose

25 μg/kg administered intravenously within 5 minutes followed by 0.15 μg/kg/min for up to 18 hours.

Indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.

Renal impairment

In patients with creatinine clearance <30 ml/min a reduction of the administered dose of tirofiban by 50% is recommended.

Discontinuation before invasive procedures

8 h